178 related articles for article (PubMed ID: 33092566)
1. RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study.
Xu R; Fathima P; Strunk T; de Klerk N; Snelling TL; Richmond PC; Keil AD; Moore HC
BMC Pediatr; 2020 Oct; 20(1):490. PubMed ID: 33092566
[TBL] [Abstract][Full Text] [Related]
2. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
[TBL] [Abstract][Full Text] [Related]
4. Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high-risk infants.
Stiboy E; Chan M; Islam MS; Saravanos GL; Lui K; Jaffe A; Homaira N
Pediatr Pulmonol; 2023 Apr; 58(4):1210-1220. PubMed ID: 36748923
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
Ordóñez JE; Huertas VM
BMC Infect Dis; 2024 Apr; 24(1):418. PubMed ID: 38641577
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation.
Yeo KT; Yung CF; Khoo PC; Saffari SE; Sng JSP; How MS; Quek BH
J Infect Dis; 2021 Jul; 224(2):279-287. PubMed ID: 33274362
[TBL] [Abstract][Full Text] [Related]
7. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
8. A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan.
Chi H; Hsu CH; Chang JH; Chiu NC; Hung HY; Kao HA; Weng LC; Huang FY; Chiu YY; Chang LY; Huang LM
PLoS One; 2014; 9(6):e100981. PubMed ID: 24971565
[TBL] [Abstract][Full Text] [Related]
9. Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals.
Zylbersztejn A; Almossawi O; Gudka N; Tompsett D; De Stavola B; Standing JF; Smyth R; Hardelid P
Br J Clin Pharmacol; 2022 Mar; 88(3):1246-1257. PubMed ID: 34478568
[TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
Resch B; Egger B; Kurath-Koller S; Urlesberger B
Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
[TBL] [Abstract][Full Text] [Related]
11. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
14. Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study.
Elhalik M; El-Atawi K; Dash SK; Faquih A; Satyan AD; Gourshettiwar N; Khan A; Varughese S; Ramesh A; Khamis E
Can Respir J; 2019; 2019():2986286. PubMed ID: 31871513
[TBL] [Abstract][Full Text] [Related]
15. Palivizumab administration in preterm infants in France: EPIPAGE-2 cohort study.
Torchin H; Rousseau J; Marchand-Martin L; Truffert P; Jarreau PH; Ancel PY
Arch Pediatr; 2018 Feb; 25(2):89-94. PubMed ID: 29395887
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Palivizumab against Respiratory Syncytial Virus: Cohort and Case Series Analysis.
Moore HC; de Klerk N; Richmond PC; Fathima P; Xu R; Keil AD; Snelling TL; Strunk T
J Pediatr; 2019 Nov; 214():121-127.e1. PubMed ID: 31378522
[TBL] [Abstract][Full Text] [Related]
17. Impact of immunoprophylaxis with palivizumab on respiratory syncytial virus infection in preterm infants less than 35 weeks in Colombian hospitals.
Galvis C; Colmenares A; Cabrales L; Ibatá L; Marulanda J; Ovalle O; Puello D; Rojas C; Africano M; Ballesteros A; Posso H
Pediatr Pulmonol; 2022 Oct; 57(10):2420-2427. PubMed ID: 35791790
[TBL] [Abstract][Full Text] [Related]
18. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
[TBL] [Abstract][Full Text] [Related]
19. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
[TBL] [Abstract][Full Text] [Related]
20. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
Priante E; Tavella E; Girardi E; Militello MA; Mardegan V; Maule MM; Dall'Agnola A; Baraldi E; Manzoni P
Am J Perinatol; 2019 Jul; 36(S 02):S77-S82. PubMed ID: 31238365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
